Why the study?
Does extreme body weight or gender affect the safety, tolerability, pharmacokinetics, and pharmacodynamics of rivaroxaban 10 mg in healthy subjects?
Does extreme body weight or gender affect the safety, tolerability, pharmacokinetics, and pharmacodynamics of rivaroxaban 10 mg in healthy subjects?
Rivaroxaban 10 mg is unlikely to require dose adjustment for body weight or gender, as extreme body weight had limited influence on its pharmacokinetics and pharmacodynamics.
Answers are grounded in this paper and cite their sources.
No dose adjustment for rivaroxaban 10 mg needed across extreme weights or gender; extends PK data supporting fixed dosing in healthy subjects.
Anticoagulants are often dose adjusted, or their use restricted, in patients with extremes of body weight. Rivaroxaban (BAY 59-7939) is a novel, oral, direct factor Xa inhibitor in clinical development. This was a randomized, single-blind, placebo-controlled, parallel-group study in healthy male and female subjects to assess the effect of extreme body weight (< or = 50 kg and >120 kg), and gender, on the safety, tolerability, pharmacokinetics, and pharmacodynamics of rivaroxaban 10 mg, compared with subjects of normal weight (70-80 kg). Rivaroxaban was well tolerated. Cmax of rivaroxaban was unaffected in subjects >120 kg but was increased by 24% in subjects weighing < or = 50 kg, resulting in a small (15%) increase in prolongation of prothrombin time, which was not considered clinically relevant. The area under the curve was unaffected by body weight or gender. No other clinically relevant differences were observed, suggesting that rivaroxaban is unlikely to require dose adjustment for body weight or gender.
No takes yet. Share an insight, caveat, or question.
Kubitza et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: